BBNX
Beta Bionics, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
19.05
▼ 0.43 (2.21%)
MARKET · —
Price
Too many bars for candle bodies at this width — showing high/low range per bar. Zoom in or pick a shorter range.
Open
19.01
Prev close
19.48
Day high
19.50
Day low
18.54
Volume
494.87K
Market cap
$857.05M
P/E (TTM)
—
52W range
8.80 – 32.71
Insider net activity
Net shares
+1.64M
Net buying
Buy transactions
18
1.73M shares
Sell transactions
26
86.99K shares
Net transactions
+44
Buys less sells
Sell : buy shares
0.1 : 1
Mixed
Insider-held shares
485.44K
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 29, 26 | FEIDER STEPHEN Chief Financial Officer |
SELL | 10.00K | $170.39K | Direct |
| Jun 29, 26 | FEIDER STEPHEN Chief Financial Officer |
SELL | 10.00K | $170.39K | Direct |
| Jun 29, 26 | FEIDER STEPHEN Chief Financial Officer |
CONVERSION | 9.88K | $50.38K | Direct |
| Jun 29, 26 | FEIDER STEPHEN Chief Financial Officer |
CONVERSION | 10.00K | $51.00K | Direct |
| Jun 24, 26 | HOPMAN MARK Officer |
SELL | 1.26K | $18.88K | Direct |
| Jun 24, 26 | JONES CHRISTY Director |
SELL | 1.41K | $21.09K | Direct |
| Jun 4, 26 | HOPMAN MARK Officer |
SELL | 275 | $3.38K | Direct |
| Jun 4, 26 | JONES CHRISTY Director |
SELL | 2.81K | $39.35K | Direct |
| Jun 2, 26 | SAINT SEAN Chief Executive Officer |
SELL | 16.87K | $212.71K | Direct |
| Jun 2, 26 | FEIDER STEPHEN Chief Financial Officer |
SELL | 6.68K | $84.17K | Direct |
| Jun 2, 26 | HOPMAN MARK Officer |
SELL | 5.33K | $67.18K | Direct |
| Jun 2, 26 | MENSINGER MIKE Officer |
SELL | 4.38K | $55.19K | Direct |
| Jun 2, 26 | RUSSELL STEVEN JON Officer |
SELL | 4.22K | $53.23K | Direct |
| May 22, 26 | LEZACK ADAM Director |
SELL | 2.00K | $21.14K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
CARNEY SEAN D |
Director | 32.21K | Stock Award(Grant) |
DEAREN DANNY L |
Director | 32.21K | Stock Award(Grant) |
FEIDER STEPHEN |
Chief Financial Officer | 165.93K | Sale |
HOPMAN MARK |
Officer | 129.35K | Sale |
MENSINGER MIKE |
Officer | 184.41K | Sale |
MICHEL GERARD J |
Director | 33.51K | Stock Award(Grant) |
PALASIS MARIA |
Director | 29.40K | Stock Award(Grant) |
RUSSELL STEVEN JON |
Officer | 173.85K | Sale |
SAINT SEAN |
Chief Executive Officer | 420.94K | Sale |
WELLINGTON HADLEY HARBOR AGGREGATOR IV, L.P. |
Beneficial Owner of more than 10% of a Class of Security | 3.90M | Purchase |
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.13
Call-heavy session
Put / call open interest
0.03
Positioning, not flow
Max pain
12.50
-34.4% from spot
ATM implied vol
152.0%
Nearest strike to spot
Skew (10% OTM)
+149.8%
Puts bid over calls
Call volume
15
Contracts, this expiry
Put volume
2
Contracts, this expiry
Heaviest call OI
20.00
111 contracts
Heaviest put OI
12.50
3 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Trailing performance
Returnvs SPY
1W
+8.42%
+9.8%
1M
+18.10%
+14.4%
3M
+79.55%
+76.5%
6M
+39.05%
+28.0%
YTD
-37.48%
-49.8%
1Y
+24.51%
+4.5%
3Y
—
-74.2%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$857.05M
Enterprise value$683.08M
Revenue (TTM)$119.01M
Gross profit$69.40M
EBITDA$-80.80M
Net income$-72.97M
EPS (TTM)$-1.60
Free cash flow$-40.29M
Total cash$180.49M
Total debt$6.51M
Book value / share$5.70
Shares outstanding44.99M
Float26.44M
Short % of float16.98%
Dividend yield—
Beta (5Y)—
Short interest
Shares short
7.60M
Prior 6.82M
Change vs prior
+11.5%
Shorts adding
% of float
16.98%
Elevated
% of shares out
16.90%
Against total outstanding
Days to cover
6.8
Crowded exit
Float
26.44M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Valuation & profitability ratios
Trailing P/E—
Forward P/E-8.23
PEG ratio—
Price / sales—
Price / book3.34
EV / revenue5.74
EV / EBITDA-8.45
Gross margin58.31%
Operating margin-79.90%
Profit margin-61.31%
Return on equity-26.16%
Return on assets-16.67%
Debt / equity2.54
Current ratio8.88
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $100.25M | $65.12M | $11.99M | $179.00K | +53.9% |
| Operating revenue | $100.25M | $65.12M | $11.99M | $179.00K | +53.9% |
| Cost of revenue | $44.71M | $29.24M | $5.69M | — | +52.9% |
| Gross profit | $55.54M | $35.89M | $6.31M | $179.00K | +54.8% |
| Research & development | $34.79M | $26.18M | $17.94M | $31.43M | +32.9% |
| Selling, general & admin | $92.43M | $54.95M | $24.21M | $34.59M | +68.2% |
| Total operating expense | $127.22M | $81.14M | $42.16M | $66.02M | +56.8% |
| Operating income | -$71.68M | -$45.25M | -$35.85M | -$65.84M | -58.4% |
| Net interest income | $10.93M | $3.91M | $1.78M | $182.00K | +179.7% |
| Pre-tax income | -$73.20M | -$54.76M | -$44.10M | -$64.75M | -33.7% |
| Net income | -$73.20M | -$54.76M | -$44.10M | -$64.75M | -33.7% |
| Net income to common | -$73.20M | -$54.76M | -$44.10M | -$64.75M | -33.7% |
| Basic EPS | -1.81 | -1.28 | -1.45 | -2.12 | -41.7% |
| Diluted EPS | -1.81 | -1.28 | -1.45 | -2.12 | -41.7% |
| EBIT | -$71.68M | -$45.25M | -$35.85M | -$64.74M | -58.4% |
| EBITDA | -$68.81M | -$42.97M | -$33.76M | -$62.65M | -60.1% |
| Basic shares | 40.53M | 42.86M | 30.50M | 30.50M | -5.4% |
| Diluted shares | 40.53M | 42.86M | 30.50M | 30.50M | -5.4% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $31.58M | $30.43M | $26.57M | $27.68M | +3.8% |
| Cash & short-term investments | $219.13M | $103.58M | $96.75M | $27.68M | +111.6% |
| Accounts receivable | $17.12M | $12.00M | $4.45M | $0 | +42.7% |
| Inventory | $21.72M | $13.32M | $1.25M | $0 | +63.1% |
| Total current assets | $267.90M | $132.92M | $103.62M | $28.47M | +101.5% |
| Property, plant & equipment | $15.23M | $11.42M | $6.20M | $6.87M | +33.3% |
| Total assets | $328.74M | $149.65M | $110.04M | $35.53M | +119.7% |
| Total current liabilities | $30.92M | $21.15M | $10.61M | $8.87M | +46.2% |
| Total debt | $7.30M | $7.25M | $4.22M | $4.13M | +0.7% |
| Total liabilities | $41.13M | $395.00M | $313.14M | $205.56M | -89.6% |
| Retained earnings | -$369.94M | -$296.74M | -$229.66M | -$185.56M | -24.7% |
| Shareholder equity | $287.61M | -$245.36M | -$203.10M | -$170.03M | +217.2% |
| Working capital | $236.98M | $111.78M | $93.02M | $19.59M | +112.0% |
| Net tangible assets | $287.61M | -$245.36M | -$203.10M | -$170.03M | +217.2% |
| Shares issued | 44.36M | 42.86M | 42.86M | 42.86M | +3.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$73.20M | -$54.76M | -$44.10M | -$64.75M | -33.7% |
| Depreciation & amortisation | $2.88M | $2.28M | $2.09M | $2.09M | +25.9% |
| Stock-based compensation | $16.38M | $6.38M | $5.66M | $6.10M | +156.6% |
| Change in working capital | -$8.99M | -$12.15M | -$5.30M | -$2.79M | +26.0% |
| Operating cash flow | -$50.92M | -$48.27M | -$32.45M | -$60.21M | -5.5% |
| Capital expenditure | -$5.30M | -$3.40M | -$402.00K | -$772.00K | -56.0% |
| Investing cash flow | -$162.81M | -$3.48M | -$69.69M | -$769.00K | -4,583.7% |
| Financing cash flow | $214.87M | $55.62M | $101.03M | $56.78M | +286.4% |
| Free cash flow | -$56.22M | -$51.67M | -$32.85M | -$60.98M | -8.8% |
| End cash position | $31.68M | $30.53M | $26.67M | $27.77M | +3.7% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Total revenue | $32.01M | $27.63M | $32.12M | $27.25M | $23.24M | +15.9% |
| Operating revenue | $32.01M | $27.63M | $32.12M | $27.25M | $23.24M | +15.9% |
| Cost of revenue | $13.11M | $11.19M | $13.18M | $12.13M | $10.73M | +17.2% |
| Gross profit | $18.90M | $16.44M | $18.94M | $15.12M | $12.50M | +15.0% |
| Research & development | $10.24M | $10.36M | $10.13M | $8.20M | $8.87M | -1.1% |
| Selling, general & admin | $34.24M | $30.35M | $24.94M | $23.97M | $23.50M | +12.8% |
| Total operating expense | $44.48M | $40.71M | $35.07M | $32.16M | $32.38M | +9.3% |
| Operating income | -$25.58M | -$24.27M | -$16.12M | -$17.04M | -$19.87M | -5.4% |
| Net interest income | $2.18M | $2.38M | $2.66M | $2.83M | $3.00M | -8.4% |
| Pre-tax income | -$23.40M | -$21.89M | -$13.47M | -$14.21M | -$16.87M | -6.9% |
| Net income | -$23.40M | -$21.89M | -$13.47M | -$14.21M | -$16.87M | -6.9% |
| Net income to common | -$23.40M | -$21.89M | -$13.47M | -$14.21M | -$16.87M | -6.9% |
| Basic EPS | -0.53 | -0.49 | -0.30 | -0.33 | -0.39 | -8.2% |
| Diluted EPS | -0.53 | -0.49 | -0.30 | -0.33 | -0.39 | -8.2% |
| EBIT | -$25.58M | -$24.27M | -$11.95M | -$17.04M | -$19.87M | -5.4% |
| EBITDA | -$24.46M | -$23.28M | -$11.01M | -$16.36M | -$19.22M | -5.1% |
| Basic shares | 44.55M | 44.44M | 44.19M | 43.63M | 43.39M | +0.2% |
| Diluted shares | 44.55M | 44.44M | 44.19M | 43.63M | 43.39M | +0.2% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $44.32M | $30.21M | $31.58M | $38.48M | $35.08M | +46.7% |
| Cash & short-term investments | $180.49M | $199.52M | $219.13M | $228.69M | $249.72M | -9.5% |
| Accounts receivable | $18.05M | $15.75M | $17.12M | $11.54M | $13.43M | +14.6% |
| Inventory | $23.92M | $23.73M | $21.72M | $20.37M | $17.32M | +0.8% |
| Total current assets | $231.03M | $247.99M | $267.90M | $270.03M | $286.07M | -6.8% |
| Property, plant & equipment | $16.56M | $16.39M | $15.23M | $14.41M | $12.50M | +1.1% |
| Total assets | $292.39M | $304.42M | $328.74M | $330.05M | $329.97M | -4.0% |
| Total current liabilities | $26.02M | $23.19M | $30.92M | $25.39M | $19.49M | +12.2% |
| Total debt | $6.51M | $6.91M | $7.30M | $7.69M | $6.69M | -5.8% |
| Total liabilities | $36.02M | $33.17M | $41.13M | $35.29M | $28.34M | +8.6% |
| Retained earnings | -$415.24M | -$391.83M | -$369.94M | -$356.47M | -$342.26M | -6.0% |
| Shareholder equity | $256.37M | $271.25M | $287.61M | $294.76M | $301.63M | -5.5% |
| Working capital | $205.02M | $224.79M | $236.98M | $244.64M | $266.59M | -8.8% |
| Net tangible assets | $256.37M | $271.25M | $287.61M | $294.76M | $301.63M | -5.5% |
| Shares issued | 44.98M | 44.56M | 44.36M | 43.99M | 43.47M | +0.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$23.40M | -$21.89M | -$13.47M | -$14.21M | -$16.87M | -6.9% |
| Depreciation & amortisation | $1.12M | $987.00K | $935.00K | $683.00K | $653.00K | +13.3% |
| Stock-based compensation | $7.02M | $5.41M | $4.30M | $4.48M | $4.80M | +29.8% |
| Change in working capital | $513.00K | -$8.21M | -$1.34M | $317.00K | -$1.50M | +106.2% |
| Operating cash flow | -$14.62M | -$23.83M | -$8.63M | -$8.73M | -$13.59M | +38.6% |
| Capital expenditure | -$1.04M | -$1.38M | -$1.90M | -$1.28M | -$1.78M | +24.5% |
| Investing cash flow | $26.93M | $21.84M | $658.00K | $9.49M | $6.17M | +23.3% |
| Financing cash flow | $1.80M | $623.00K | $1.06M | $2.65M | $42.00K | +189.1% |
| Free cash flow | -$15.66M | -$25.21M | -$10.53M | -$10.01M | -$15.37M | +37.9% |
| End cash position | $44.42M | $30.31M | $31.68M | $38.59M | $35.17M | +46.6% |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.56 | -0.36 | +35.1% |
| Mar 2026 | -0.45 | -0.36 | +21.1% |
| Dec 2025 | -0.38 | -0.19 | +49.4% |
| Sep 2025 | -0.41 | -0.33 | +19.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.51 | 2 | $35.04M | +28.6% |
| Next quarter | -0.51 | 2 | $39.16M | +21.9% |
| Current year | -1.90 | 2 | $133.88M | +33.6% |
| Next year | -2.32 | 2 | $179.65M | +34.2% |
Analyst targets & ownership
Mean target$20.31
High target$30.40
Low target$14.00
Implied upside6.61%
Analyst count11
ConsensusBUY
Strong buy / Buy1 / 7
Hold4
Sell / Strong sell0 / 0
Held by insiders1.08%
Held by institutions112.09%
Institutions holding187
Price targets, consensus spread, insider and institutional ownership.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 21, 26 | William Blair | INITIATED | — | Market Perform |
| Jul 15, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Jul 13, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| May 27, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
| May 18, 26 | B of A Securities | MAINTAINED | Neutral | Neutral |
| Apr 22, 26 | Leerink Partners | MAINTAINED | Outperform | Outperform |
| Apr 22, 26 | Stifel | MAINTAINED | Buy | Buy |
| Apr 15, 26 | Truist Securities | MAINTAINED | Buy | Buy |
| Apr 9, 26 | Goldman Sachs | MAINTAINED | Buy | Buy |
| Feb 18, 26 | Stifel | MAINTAINED | Buy | Buy |
| Feb 18, 26 | Baird | MAINTAINED | Neutral | Neutral |
| Feb 4, 26 | Stifel | MAINTAINED | Buy | Buy |
Moving averages & technicals
SMA 10
18.21
+4.60% from price
SMA 20
16.40
+16.15% from price
SMA 50
16.11
+18.24% from price
SMA 100
13.61
+39.99% from price
SMA 200
17.12
+11.29% from price
EMA 12
17.93
+6.24% from price
EMA 26
16.93
+12.51% from price
EMA 50
15.96
+19.34% from price
RSI (14)
62.8
Neutral
MACD (12,26,9)
1.00
Hist 0.38
ATR (14)
1.27
6.65% of price
Realised vol 30D
76.4%
Annualised
Bollinger upper
20.60
20, 2σ
Bollinger lower
12.21
20, 2σ
50 / 200 cross
Death
16.11 vs 17.12
Trend bias
Above 200
+11.29%
Risk profile
Beta vs SPY
1.31
More volatile than market
Correlation to SPY
0.21
Largely independent
Realised vol 30D
76.4%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-72.3%
Peak to trough
Max drawdown 5Y
-72.3%
Peak to trough
ATR 14
1.27
6.65% of price
Beta (reported)
—
5Y monthly, from filing
SEC filings
Periodic Financial Reports
10-Q · 2026-07-29
Corporate Changes & Voting Matters
8-K · 2026-05-22
Corporate Changes & Voting Matters
8-K · 2026-05-21
Corporate Changes & Voting Matters
8-K · 2026-04-21
Proxy Statements
DEF 14A · 2026-04-10
Offering Registrations
S-3ASR · 2026-02-24
Corporate Changes & Voting Matters
8-K · 2026-02-17
Corporate Changes & Voting Matters
8-K · 2026-01-30
Headlines
BofA Securities Adjusts Price Target on Beta Bionics to $18 From $15.50
MT Newswires · 10d ago
BofA Securities Adjusts Beta Bionics Price Target to $18 From $15.50
MT Newswires · 11d ago
Beta Bionics (BBNX) Q2 2026 Earnings Call Transcript
Motley Fool · 15d ago
Beta Bionics, Inc. Q2 2026 Earnings Call Summary
Moby · 23d ago
Beta Bionics Q2 Earnings Call Highlights
MarketBeat · 24d ago
Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates
Zacks · 24d ago
Beta Bionics Announces Second Quarter 2026 Financial Results and Updates Full Year 2026 Guidance
GlobeNewswire · 24d ago
UBS Adjusts Price Target on Beta Bionics to $22 From $24, Maintains Buy Rating
MT Newswires · 25d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.